Phase III Clinical Study of Recombinant Erythropoiesis Stimulating Protein Injection (rESP) in the Treatment of Anemia in Hemodialysis Patients With Chronic Renal Failure
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.
Also called NCT05211167
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 300 participants
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Registry
-
NCT05211167
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT05211167. Randomized; no masking; primary purpose treatment. Start 2021-07-01 (actual); primary completion 2023-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase III Clinical Study of Recombinant Erythropoiesis Stimulating Protein Injection (rESP) in the Treatment of Anemia in Hemodialysis Patients With Chronic Renal Failure
- Condition
- Kidney Failure, Chronic
- Condition
- Hemodialysis
- Intervention (Drug)
- Human Erythropoiesis Injection (CHO cell)
- Intervention (Drug)
- Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)
- Lead sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Record details
- Record id
cardio:ct-nct05211167- Content hash
3a129d645237904d428104a3ac048954b7043a3ddbaf7f6d2b26bc6e81039fcc